Kimmoun, Antoine http://orcid.org/0000-0002-5443-2074
Duarte, Kevin
Harjola, Veli-Pekka
Tarvasmäki, Tuukka
Levy, Bruno
Mebazaa, Alexandre
Gibot, Sebastien
Koniari, Katerina
Voumvourakis, Astrinos
Karavidas, Apostolos
Parissis, John
Sans-Rosello, Jordi
Vila, Montserrat
Duran-Cambra, Albert
Sionis, Alessandro
Parenica, Jiri
Stipal, Roman
Ludka, Ondrej
Palsuva, Marie
Ganovska, Eva
Kubena, Petr
Spinar, Jindrich
Lindholm, Matias G.
Hassager, Christian
Køber, Lars
Bäcklund, Tom
Lassus, Johan
Jurkko, Raija
Tolppanen, Heli
Nieminen, Markku S.
Järvinen, Kristiina
Nieminen, Tuomo
Pulkki, Kari
Soininen, Leena
Sund, Reijo
Tierala, Ilkka
Tolonen, Jukka
Varpula, Marjut
Korva, Tuomas
Pietilä, Mervi
Pitkälä, Anne
Marino, Rossella
Di Somma, Salvatore
Metra, Marco
Bulgari, Michela
Lazzarini, Valentina
Carubelli, Valentina
Sousa, Alexandra
Silva-Cardoso, Jose
Sousa, Carla
Paiva, Mariana
Rangel, Inês
Almeida, Rui
Pinho, Teresa
Maciel, Maria Júlia
Banaszewski, Marek
Stepinska, Janina
Skrobisz, Anna
Góral, Piotr
Zeymer, Uwe
Thiele, Holger
,
Funding for this research was provided by:
Aarne Koskelon Säätiö
Finnish Cardiac Foundation
Finnish State funding for university-level health research
Article History
Received: 3 December 2020
Accepted: 16 February 2021
First Online: 7 March 2021
Declaration
:
: Antoine Kimmoun. A K received speaker’s honoraria for lectures from Baxter, Aguettant and Aspen. Alexandre Mebazaa. AM reports personal fees from Orion, grants and personal fees from Roche, personal fees from Servier, personal fees from Otsuka, personal fees from Philips, grants and personal fees from Adrenomed, personal fees from NeuroTronik, grants and personal fees from 4TEEN4, personal fees from Sanofi. Sébastien Gibot. S G is a cofounder of INOTREM, a company developing an inhibitor of TREM-1. The remaining author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.